Fig. 3 | Scientific Reports

Fig. 3

From: Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology

Fig. 3

Comparison of CancerMaster and the commercial panel TSO500 using 23 cancer tissue samples. This figure compares the CancerMaster panel with the commercial panel TSO500 using 23 cancer tissue samples. One missense mutation in ERBB2 was reported in CancerMaster but not in TSO500, and one fusion and four CNVs were only reported in TSO500. CNV, copy number variant.

Back to article page